- Home
- HIVE vs ATYR Comparison
HIVE vs ATYR Comparison
Compare HIVE & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HIVE
- ATYR
- Stock Information
- Founded
- HIVE 1987
- ATYR 2005
- Country
- HIVE Canada
- ATYR United States
- Employees
- HIVE N/A
- ATYR N/A
- Industry
- HIVE
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HIVE
- ATYR Health Care
- Exchange
- HIVE Nasdaq
- ATYR Nasdaq
- Market Cap
- HIVE 368.3M
- ATYR 330.7M
- IPO Year
- HIVE N/A
- ATYR 2015
- Fundamental
- Price
- HIVE $2.00
- ATYR $3.40
- Analyst Decision
- HIVE Strong Buy
- ATYR Strong Buy
- Analyst Count
- HIVE 7
- ATYR 6
- Target Price
- HIVE $7.79
- ATYR $18.60
- AVG Volume (30 Days)
- HIVE 10.5M
- ATYR 1.7M
- Earning Date
- HIVE 02-11-2025
- ATYR 05-01-2025
- Dividend Yield
- HIVE N/A
- ATYR N/A
- EPS Growth
- HIVE N/A
- ATYR N/A
- EPS
- HIVE N/A
- ATYR N/A
- Revenue
- HIVE $120,999,000.00
- ATYR $235,000.00
- Revenue This Year
- HIVE $2.40
- ATYR N/A
- Revenue Next Year
- HIVE $179.59
- ATYR $1,299.74
- P/E Ratio
- HIVE N/A
- ATYR N/A
- Revenue Growth
- HIVE 26.29
- ATYR N/A
- 52 Week Low
- HIVE $1.78
- ATYR $1.42
- 52 Week High
- HIVE $5.54
- ATYR $4.66
- Technical
- Relative Strength Index (RSI)
- HIVE 29.85
- ATYR 45.51
- Support Level
- HIVE $1.84
- ATYR $2.95
- Resistance Level
- HIVE $2.29
- ATYR $3.26
- Average True Range (ATR)
- HIVE 0.19
- ATYR 0.39
- MACD
- HIVE -0.03
- ATYR -0.09
- Stochastic Oscillator
- HIVE 19.64
- ATYR 35.55
About HIVE HIVE Digital Technologies Ltd.
HIVE Digital Technologies Ltd is in the business of providing infrastructure solutions in the blockchain industry. It focuses on the mining and sale of digital currencies. Its geographical segments include Canada, Sweden, Iceland, Switzerland, and Bermuda, out of which the majority of the revenue comes from Bermuda.
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.